Karuna Therapeutics Inc (OQ:KRTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 33 Arch St Ste 3110
BOSTON MA 02110-1424
Tel: N/A
Website: https://karunatx.com
IR: See website
Key People
Steven M. Paul
Chairman of the Board, President, Chief Executive Officer
Troy A. Ignelzi
Chief Financial Officer
Andrew Craig Miller
Chief Operating Officer
Giorgio Attardo
Vice President, CMC and Preclinical Development
Stephen K. Brannan
Chief Medical Officer
Business Overview
Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer's disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.
Financial Overview
For the three months ended 31 March 2020, Karuna Therapeutics Inc revenues was not reported. Net loss decreased 28% to $8.7M. Lower net loss reflects Research and development decrease of 54% to $3.1M (expense), Stock-based Compensation in SGA decrease of 88% to $349K (expense), Interest income increase from $115K to $1.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.56 to -$0.33.
Employees: 19 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $1,906M as of Jun 30, 2020
Annual revenue (TTM): $0.00M as of Jun 30, 2020
EBITDA (TTM): -$43.82M as of Jun 30, 2020
Net annual income (TTM): -$40.61M as of Jun 30, 2020
Free cash flow (TTM): -$33.32M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 26,130,120 as of Apr 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.